Difference between revisions of "Dermatofibrosarcoma protuberans"
Jump to navigation
Jump to search
(→NCCN) |
(→NCCN) |
||
| Line 19: | Line 19: | ||
*'''2012:''' Miller et al. [https://doi.org/10.6004/Jnccn.2012.0032 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/22393193/ PubMed] | *'''2012:''' Miller et al. [https://doi.org/10.6004/Jnccn.2012.0032 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/22393193/ PubMed] | ||
*'''2007:''' Miller et al. [https://doi.org/10.6004/Jnccn.2007.0048 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/17509257/ PubMed] | *'''2007:''' Miller et al. [https://doi.org/10.6004/Jnccn.2007.0048 Dermatofibrosarcoma protuberans.] [https://pubmed.ncbi.nlm.nih.gov/17509257/ PubMed] | ||
| − | *'''2004:''' | + | *'''2004:''' Authors not listed. [https://doi.org/10.6004/Jnccn.2004.0006 Dermatofibrosarcoma protuberans. Clinical practice guidelines in oncology.] [https://pubmed.ncbi.nlm.nih.gov/19777697/ PubMed] |
=All lines of therapy= | =All lines of therapy= | ||
Revision as of 17:46, 29 November 2023
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: these are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
2 variants on this page
|
Guidelines
Given the rapid change in evidence in many areas of hematology/oncology, readers are encouraged to consider any article published 5+ years ago to be for historical purposes, only.
NCCN
- 2014: Bichakjian et al. Dermatofibrosarcoma protuberans, version 1.2014 PubMed
- 2012: Miller et al. Dermatofibrosarcoma protuberans. PubMed
- 2007: Miller et al. Dermatofibrosarcoma protuberans. PubMed
- 2004: Authors not listed. Dermatofibrosarcoma protuberans. Clinical practice guidelines in oncology. PubMed
All lines of therapy
Imatinib monotherapy
Regimen variant #1, 400 mg/day
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Rutkowski et al. 2010 (SWOG S0345) | 2005-2006 | Phase 2, fewer than 20 pts |
Regimen variant #2, 800 mg/day
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Rutkowski et al. 2010 (EORTC 62027) | 2004-2007 | Phase 2, fewer than 20 pts (RT) |
Targeted therapy
- Imatinib (Gleevec) 400 mg PO twice per day
Continued indefinitely, unless complete (R0) surgical resection became possible
References
- EORTC 62027: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00085475
- SWOG S0345: Rutkowski P, Van Glabbeke M, Rankin CJ, Ruka W, Rubin BP, Debiec-Rychter M, Lazar A, Gelderblom H, Sciot R, Lopez-Terrada D, Hohenberger P, van Oosterom AT, Schuetze SM; EORTC Soft Tissue and Bone Sarcoma Group; SWOG. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol. 2010 Apr 1;28(10):1772-9. Epub 2010 Mar 1. link to original article contains dosing details in manuscript link to PMC article PubMed NCT00084630